Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models
Compose a Response to This Article
Other responses
No responses have been published for this article.
